With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Five GLP-1 products will collectively bring in $470 billion by 2030, and the market leaders are working to hold back ...

Novo Nordisk and Eli Lilly are ... what it sees as abuses in the patent system. Ozempic, which also has approvals in chronic kidney disease and heart disease, accounted for about half of that ...

Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal.

Sales of Novo Nordisk’s fast-growing GLP ... even further by new outcomes data showing that Ozempic can reduce the risk of chronic kidney disease in patients with type 2 diabetes, while Wegovy ...

Prescribing of drugs between 2021 and 2023 shifted dramatically for both type 2 diabetes and weight loss for people with ...

Pfizer and Eli Lilly reporting significant - and opposing - news in the GLP-1 industryLexaria's technology could enhance performance and lower side effects KELOWNA, BC / ACCESS Newswire / April 23, ...

The drugmaker Lilly announced topline results of a clinical trial of a new pill in the same drug class as injectables like ...

In an hour-long meeting at Eli Lilly and Company’s headquarters in Indianapolis on April 15, the pharmaceutical company’s top ...

The U.S. Food and Drug Administration and the pharmaceutical company Novo Nordisk are urging consumers to be on the lookout ...